Prospective pharmaco-epidemiological study aiming to describe the management of relapsed or refractory chronic lymphocytic leukemia (CLL) patients retreated with MabThera® FRESH-PEF74091-en Camille BACHOT Prospective pharmaco-epidemiological study aiming to describe the management of relapsed or refractory chronic lymphocytic leukemia (CLL) patients retreated with MabThera® PERLE FRESH-PEF74091-en 74091 FRESH-PEF74091 NCT01488162 F. HOFFMANN-LA ROCHE AG Epidemiology France Portal (PEF) null ;Medical data center rituximab Hematology Neoplasms of haematopoietic or lymphoid tissues Healthcare system determinants: Use of care Healthcare system determinants Primary Objective: To describe the chemotherapy regimens combined with MabThera® in relapsed or refractory CLL patients having previously received a first or second-line treatment containing MabThera® Secondary Objectives: - Describe efficacy of treatment: overall response (OR), complete response (CR), partial response (PR), progression-free survival (PFS), time to next treatment (TTNT), overall survival (OS) in the total cohort and in the following subgroups: refractory (Yes/No), age (< or >= 70 years), 17p deletion (Yes/No), 11q deletion (Yes/No). - Describe the choice of chemotherapy regimen in patient subgroups defined as: refractory (Yes/No), age (< or >= 70 years), 17p deletion (Yes/No), 11q deletion (Yes/No) - Describe MabThera® treatment regimens (dose, number of cycles), - Describe safety of treatment: all adverse events occurring during the study, - Describe hospitalizations related to an adverse event throughout the study period. Exploratory Objectives: -Analysis of maximal response duration at last line before inclusion will be performed quantitatively and by classes, overall and by age, in all patients and according to number of previous lines of treatment. - Primary criterion will be also described according to the following subgroups: - last previous treatment before current relapse included the same/not the same chemotherapy treatment as first induction treatment - report of Normalized creatinine clearance result < 60 (ml/min/1.73 m²) at baseline (yes/no) (renal insufficiency). - In patients with HBs antigen positive or anti-HBc antibody positive, analysis of HBV prophylaxis and HBV treatment will be performed by visit - Multinomial regression on choice of chemotherapy given at first cycle - Logistic model on response null France Individuals Patients population Male Female Young Adult (19 to 24 years) Adult (25 to 44 years) Middle Aged (45 to 64 years) Aged (65 to 79 years) Aged, 80 and over (80 years and more) Inclusion criteria: - Adult patient (age >= 18 years) - Presenting with chronic lymphocytic leukemia confirmed by immunophenotyping of circulating lymphocytes (Matutes score >= 4) - In relapse or refractory after a first or second line of treatment - Receiving at least one line of treatment containing MabThera® - MabThera® treatment planned for current relapse - Having received oral and written information about the study and having raised no objections to computer processing of his/her personal data. Patient with Richter syndrome - Patient with life expectancy < 6 months - Patient who received 3 or more previous treatment lines* - Patient previously enrolled in this study Clinical data CDISC like GCP/GVP Other Through independent healthcare practitioners < 500 individuals Converting or copying information into a structured record Observational Study Observational Study 327 Unknown Restricted access Access on specific project only